2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10913
    Danegaptide 943134-39-2 98%
    Danegaptide (GAP-134) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect.
    Danegaptide
  • HY-116218
    Amelparib 1227156-72-0 99.17%
    Amelparib (JPI-289 free base) is a potent, orally active, and water-soluble inhibitor of PARP-1. Amelparib inhibits PARP-1 activity (IC50=18.5 nM) and cellular PAR formation (IC50=10.7 nM) in the nanomolar range. Amelparib is a potential neuroprotective agent. Amelparib has the potential for the research of acute ischaemic stroke.
    Amelparib
  • HY-15306S
    Eltrombopag-13C4 1217230-31-3
    Eltrombopag-13C4 (SB-497115-13C4) is 13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells.
    Eltrombopag-13C4
  • HY-18204S
    Valsartan-d9 1089736-73-1 ≥99.0%
    Valsartan-d9 is deuterium labeled valsartan. Valsartan is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
    Valsartan-d9
  • HY-A0093S
    Mexiletine-d6 hydrochloride 1329835-60-0 99.88%
    Mexiletine-d6 (hydrochloride) is a deuterium labeled Mexiletine hydrochloride (KOE-1173 hydrochloride). Mexiletine hydrochloride, a Class IB antianhythmic, is a non-selective voltage-gated sodium channel blocker.
    Mexiletine-d6 hydrochloride
  • HY-B0589E
    Atorvastatin hemicalcium trihydrate 344920-08-7 99.70%
    Atorvastatin hemicalcium trihydrate is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium trihydrate inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
    Atorvastatin hemicalcium trihydrate
  • HY-B0753S
    Gliclazide-d4 1185039-30-8 98%
    Gliclazide-d4 (S1702 D4) is the deuterium labeled Gliclazide. Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Gliclazide is used as an antidiabetic.
    Gliclazide-d4
  • HY-B0968S
    Trimetazidine-d8 dihydrochloride 1219795-37-5 99.87%
    Trimetazidine-d8 (dihydrochloride) is the deuterium labeled Trimetazidine dihydrochloride. Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor.
    Trimetazidine-d8 dihydrochloride
  • HY-10163AS
    Dabigatran-d4 hydrochloride ≥98.0%
    Dabigatran-d4 (hydrochloride) is deuterium labeled Dabigatran, which is a reversible and selective, direct thrombin inhibitor (DTI) with a Ki value of 4.5 nM.
    Dabigatran-d4 hydrochloride
  • HY-116218C
    Amelparib hydrochloride 98.37%
    Amelparib (JPI-289) hydrochloride is a potent, orally active, and water-soluble inhibitor of PARP-1. Amelparib hydrochloride inhibits PARP-1 activity (IC50 = 18.5 nM) and cellular PAR formation (IC50 = 10.7 nM). Amelparib hydrochloride is a potential neuroprotective agent. Amelparib hydrochloride has the potential for the research of acute ischaemic stroke.
    Amelparib hydrochloride
  • HY-13715AR
    Norepinephrine hydrochloride (Standard) 329-56-6 99.58%
    Norepinephrine (hydrochloride) (Standard) is the analytical standard of Norepinephrine (hydrochloride). This product is intended for research and analytical applications. Norepinephrine (Levarterenol; L-Noradrenaline) hydrochloride is a potent adrenergic receptor (AR) agonist. Norepinephrine activates α1, α2, β1 receptors[1][2][3][4].
    Norepinephrine hydrochloride (Standard)
  • HY-10217
    Thrombin Inhibitor 2 312904-62-4 99.92%
    Thrombin Inhibitor 2 is a small molecule direct thrombin inhibitor, extracted from US8541580B2. Thrombin Inhibitor 2 has antithrombotic activity.
    Thrombin Inhibitor 2
  • HY-10259
    PD 123319 130663-39-7 98%
    PD 123319 (ditrifluoroacetate) is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.
    PD 123319
  • HY-12981
    RG7713 920022-47-5 99.92%
    RG7713 (RO5028442) is a highly potent and selective Brain-Penetrant Vasopressin 1a (V1a) receptor antagonist with Kis of 1 nM (hV1a) and 39 nM (mV1a).
    RG7713
  • HY-A0182
    Felypressin 56-59-7 99.62%
    Felypressin (PLV-2) is a non-catecholamine vasoconstrictor and a vasopressin 1 agonist. Felypressin is widely used in dental procedures.
    Felypressin
  • HY-B0371
    Terazosin 63590-64-7 98%
    Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment.
    Terazosin
  • HY-10064S
    Ticagrelor-d7 1265911-55-4
    Ticagrelor-d7 is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
    Ticagrelor-d7
  • HY-108656
    MRS2365 436847-09-5 98%
    MRS2365 is a potent and selective P2Y1 receptor (EC50=0.4 nM) /[35S]GTPγS binding/β-arrestin 2 recruitment agonist with an EC50 of 0.4 nM. MRS2365 relieves mechanical allodynia and increases mechanical sensitivity. MRS2365 shows little agonist or antagonist activity at the P2Y12 or P2Y13 receptors.
    MRS2365
  • HY-112197
    PKG drug G1 374703-78-3 99.11%
    PKG agent G1 targets C42 of PKG Iα. PKG agent G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.
    PKG drug G1
  • HY-112911
    Endothelial lipase inhibitor-1 1466427-02-0 98.02%
    Endothelial lipase inhibitor-1 is a potent endothelial lipase inhibitor with an IC50 of 49 nM.
    Endothelial lipase inhibitor-1
Cat. No. Product Name / Synonyms Application Reactivity